04/09/2024 15:00 |
Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD |
03/28/2024 15:00 |
Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation |
03/27/2024 17:00 |
Abilify Maintena 960 mg approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia |
03/15/2024 15:30 |
Otsuka and Sumitomo Revise License Agreement |
03/15/2024 08:00 |
Partial Correction to the Notice of the 16th Annual Shareholders Meeting (for FY2023) |
02/28/2024 08:00 |
Notice of the 16th Annual Shareholders Meeting (for FY2023) |
02/16/2024 15:30 |
[Delayed]Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 [IFRS] |
02/16/2024 11:00 |
[Delayed]Notice Regarding Revision of Restricted Stock Compensation Plan |
02/16/2024 11:00 |
[Delayed]Notice of Introduction of a Special Incentive Scheme through the Otsuka Group Employee Stock Ownership Plan |
02/14/2024 13:30 |
Notice of Payment of Dividends |
02/13/2024 08:00 |
Notice Regarding Revisions of Consolidated Results Forecast for FY2023 |
12/22/2023 15:00 |
Otsuka Obtains the Additional Indication of Adjunctive Treatment of Major Depressive Disorder for Rexulti in Japan |
12/01/2023 08:00 |
Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Bonafide Health, a provider of women's health products |
11/08/2023 08:30 |
Otsuka Medical Devices and Recor Medical Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension |
11/06/2023 13:00 |
Otsuka Announces Personnel Changes |
11/01/2023 00:30 |
Environmental report 2022 |
10/31/2023 13:30 |
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2023[IFRS] |
10/31/2023 13:00 |
Otsuka Applies in Japan for the Additional Indication for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti |
10/31/2023 00:30 |
Integrated report 2022 |
09/07/2023 18:00 |
Otsuka and Lundbeck Announce Topline Results from Two P3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of PTSD |
09/01/2023 08:00 |
Notice regarding transfer of sub-subsidiary |
08/23/2023 10:00 |
OMD and Recor Announce Positive Vote from U.S. FDA Advisory Committee Meeting on the Paradise uRDN System for the Treatment of Hypertension |
07/31/2023 13:30 |
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2023 [IFRS] |
07/31/2023 08:30 |
Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia |
07/25/2023 15:00 |
Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2023 |
06/27/2023 08:30 |
Otsuka Pharmaceutical announces positive results of P3 trial in Japan showing reduced agitation in patients with AD treated with brexpiprazole |
05/12/2023 13:30 |
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2023 [IFRS] |
05/11/2023 12:30 |
Otsuka and Lundbeck Announce U.S. FDA Approval of sNDA for REXULTI for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease |
05/02/2023 15:00 |
Otsuka Pharmaceutical Factory completes acquisition of additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited |
04/28/2023 16:00 |
Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation |
04/28/2023 10:15 |
FDA Approves Otsuka's ABILIFY ASIMTUFII, Two-month, LAI for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder |